课题基金 / 基金详情

Cell-Permeable Peptides for Mitochondrial Protection

Cell-Permeable Peptides for Mitochondrial Protection
用于线粒体保护的细胞渗透肽
批准号:
6763598
负责人:
HAZEL H SZETO
金额:
$19.43万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-04-01 至 2006-03-31

项目摘要

项目成果

HAZEL H SZETO的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The application is submitted in response to the Program Announcement (PAR-02-138) requesting applications for exploratory/developmental projects in translational research. This proposal seeks to identify candidate therapeutics for neurodegenerative disorders. We have recently discovered a small lipophilic cationic peptide DAPL (Dmt-D-Arg-Phe-Lys-NH2, where Dmt = 2', 6'-dimethyltyrosine) that is cell permeable and selectively targets mitochondria. Preliminary studies with isolated mouse liver mitochondria have shown that this small peptide can protect against mitochondrial permeability transition and swelling, and reduce accumulation of reactive oxygen species. By protecting against mitochondrial dysfunction, this peptide may potentially be useful in the treatment of numerous neurodegenerative disorders. We are now seeking short-term support to further explore the pharmacology of this lead peptide analog in protecting brain mitochondria against various mitochondrial toxins, and to discover new analogs of this peptide that might lead directly to a therapy development project for a particular neurological disorder. Our specific aims are as follows: 1) To examine the ability of DAPL to protect mitochondria dysfunction caused by calcium overloading, 3-nitropropionic acid (3NPA), 1-methyl-4-phenylpyridium ion (MPP+), and t-butyl hydroperoxide (tBHP; 2) To examine the ability of DAPL to protect against cell death caused by glutamate, 3NPA, MPP +, and tBHP; 3) To carry out structure-activity relationship (SAR) studies with DAPL analogs to identify the optimal peptide analog for further preclinical development. The results from these exploratory studies will guide us to the development of preclinical animal studies for evaluating the therapeutic potential of DAPL analogs in the treatment of stroke and various neurodegenerative disorders, including Parkinson's disease, Huntington's disease and Alzheimer's disease. Potential collaborators for the animal studies have already been identified.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PROJECT #2 - PHARMACOKINETICS PROJECT
PROJECT # 3 - PHARAMCOLOGY PROJECT
Core A - Administrative Core
Mitoprotective and antioxidant peptides for DM treatment